BDD Press Releases
BDD’s Phase 1 Trial Reports Positive Phase I Results for Novel Cognitive Impairment Associated with Schizophrenia Treatment
BDD is delighted to have supported Monument Therapeutics in conducting…
In the News – BDD Taking Years Off Drug Development
SCOTTISH COMPANY TAKING YEARS…
BDD’s OralogiK™ Technology Powers Advancement of A Once-Daily Anxiety Treatment
BDD Pharma Ltd. is pleased to announce the advancement of another…
BDD Pharma opens brand new GMP manufacturing facility following £2m in funding
Media release
8 April 2025
BDD Pharma opens brand…
BDD’s OralogiK™ technology dosed in Parkinson’s patients for the first time. – Phase 1b trial of CP-012
BDD's OralogiK™ technology dosed in Parkinson's patients for…
Contera Pharma and BDD Pharma announce dosing of first subject in a Phase 1 trial of CP-012, a novel formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
Contera Pharma, a biotech company developing…
BDD secures £2M to fuel expansion in early phase clinical trials following record year
BDD secures £2M to fuel expansion in early phase clinical trials…
BDD Pharma Ltd Unveils Updated Logo for 2023
Glasgow, Scotland, United Kingdom – BDD Pharma Ltd, a…
BDD Pharma signs agreement with Contera Pharma for development of a novel tablet formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
BDD Pharma signs agreement with Contera Pharma for development…
Claire Madden-Smith joins BDD Pharma Board as Non-Executive Director
BDD PHARMA LIMITED
For immediate release – June 13th 2022
Claire…